Dishman Pharma gets EIRs for 3 sites from USFDA

Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report from the US health regulator for three of its facilities.

"Company's wholly owned subsidiary Carbogen Amcis AG, Switzerland has successfully completed United States Food and Drug Administration (USFDA) inspection for its two sites located at Aarau and Neuland without any adverse observations," Dishman Pharmaceuticals and Chemicals said in a BSE filing.

It has received the Establishment Inspection Report (EIR) for the same, it added.

"Now the company has the above two sites in addition to Bubendorf in Switzerland, which are approved by the USFDA, Dishman said.

The company's site at Naroda has also completed successful USFDA inspection and received EIR for the same, the company added.

Shares of Dishman Pharmaceuticals and Chemicals today closed 2.66 per cent up at Rs 136.85 per scrip on BSE. PTI AKT SRK .